Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Uterine Leiomyoma
Daily ganirelix treatment reduces volume of uterus and fibroids
June 23rd, 2005
Daily ganirelix treatment reduces volume of the uterus and uterine leiomyomas (fibroids), indicate study data. P.A. Flierman and colleagues, OLVG, Amsterdam, examined the "maximal volume reduction of leiomyomas and uterus and the duration of treatment required to reach these reductions" in premenopausal women receiving a daily gonadatropin releasing hormone (GnRH) antagonist called ganirelix. In the open-label study, 20 premenopausal women with symptomatic fibroids, who were scheduled for surgery received 2 mg daily ganirelix injected subcutaneously. "Prior to the first injection and weekly during treatment, the volume of...
Source: Women's Health Weekly (2005-06-23)
|
